4basebio Plc Director/PDMR Shareholding

 
TIDM4BB 
 
12 May 2022 
 
                                 4basebio plc 
                                (the "Company") 
 
 
                              Directors' Dealings 
 
4basebio PLC (AIM: 4BB), the specialist life sciences group focused on 
exploiting intellectual property in the field of cell and gene therapies and 
DNA vaccines, announces that, on 12 May 2022, directors of the Company 
purchased shares in the Company as follows: 
 
Director        Total Number of   Average Price      Beneficial      Beneficial 
                         shares   per Share (p)         Holding    Holding as a 
                      Purchased                       Following   Percentage of 
                                                       Purchase    Issued Share 
                                                                        Capital 
 
Heikki                    3,000            470p       1,252,453          10.17% 
Lanckriet 
 
David Roth                4,000          483.5p         312,000           2.53% 
 
This announcement contains inside information for the purposes of Article 7 of 
EU Regulation 596/2014. 
 
For further enquiries, please contact: 
 
4basebio plc                                            [phone] 
 
Heikki Lanckriet, CEO 
 
Cairn Financial Advisers LLP (Nominated                 [phone] 
Adviser) 
 
Jo Turner / Sandy Jamieson 
 
finnCap Ltd (Broker)                                    [phone] 
 
Geoff Nash/Richard Chambers/Charlotte 
Sutcliffe 
 
 
Notification and public disclosure of transactions by persons discharging 
managerial responsibilities and persons closely associated with them 
 
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 
596/2014 
 
1. Details of the person discharging managerial responsibilities/person closely 
associated 
 
 a. Name 
 
             1.  Heikki Lanckriet 
 
             2. David Roth 
 
2. Reason for notification 
 
 a. Position/Status 
 
            1. Chief Executive Office 
 
            2. Chief Financial Officer 
 
        b. Initial notification/ Amendment          Initial 
 
3. Details of the issuer, emission allowance market participant, auction 
platform, auctioneer or auction monitor 
 
 a. Name                                       4basebio plc 
 
        b. LEI                                           213800E2DX9EAIUNCB30 
 
4. Details of the transaction(s): section to be repeated for (i) each type of 
instrument; (ii) each type of transaction; (iii) each date; and (iv) each place 
where transactions have been conducted 
 
 a. Description of the financial instrument, type Ordinary Shares of instrument 
 
    Identification Code                        ISIN: GB00BMCLYF79 
 
 b. Nature of the transaction               Acquisition of ordinary shares 
 
 c. Price(s) and volume(s)               Volume(s)               Price (p) 
 
 
 1.                                                         3,000 
                         470p 
 2.                                                         3,000 
            480p 
 
d. Aggregated information 
 
 
1. 
- Aggregated Volume                       3,000 
- Price                                               470p pence per share 
 
2. 
- Aggregated Volume                        4,000 
- Price                                                 483.5p pence per share 
 
 
e. Date of the transaction               12/05/2022 
 
 
f. Place of the transaction London Stock Exchange, AIM 
 
 
 
END 
 
 

(END) Dow Jones Newswires

May 12, 2022 09:28 ET (13:28 GMT)